The Catalyst: 10/19/2012
At the heart of any productive relationship or venture is trust. In the biopharmaceutical sector, the integrity of our products, our research – and ultimately the faith that physicians and patients have in medicines – requires trust. And it’s something that must be earned.
A blog post in yesterday’s New York Times and a related study in the New England Journal of Medicine touch on the issue of trust, calling for greater transparency in biomedical research and inferring that bias in research or patient care is an obstacle to achieving such trust. We agree.
The practice of modern medicine requires the best available information – physicians need to know the latest developments from biopharmaceutical companies about new and existing therapies and companies benefit from feedback on patient use of medicines from physicians and other health professionals. Read more